Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...

Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of Twist Bioscience in a research ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (LSE:0J5Q) from Outperform to Market Perform. As of January 29, 2025, the average one-year price ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $70.37.